clinical trial · NCT05919537
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Hummingbird Bioscience·phase1·active not recruiting·n = 68
Non-Small Cell Lung CancerPancreatic CancerLocally Advanced Solid TumorMetastatic Solid TumorHMBD-001DocetaxelNab-paclitaxelGemcitabine
brief summary
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
started
Sep 6, 2023
primary completion
Mar 1, 2031
completion
Mar 1, 2031
last updated
Apr 18, 2025
official title
A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol